

Tabla 1. Estudios con FOLFIRI/antiangiogénicos

SG:supervivencia global ; SLP:supervivencia libre de progresión;TR:tasa de respuestas.

		Aflibercept	Ramucirumab	Bevacizumab
SG	Placebo	12.06 ms (11.07 - 13.11)	11.7 ms (10.8 – 12.7)	9.8 ms (8.9 – 10.7)
	Brazoexperimental	13.50 ms (12.52 - 14.95)	13.3 ms (12.4 – 14.5)	11.2 ms (10.4 – 12.2)
	Δ SG	1.44 ms	1.6 ms	1.4 ms
	HR	0.817 (0.713 - 0.937)	0.84 (0.73 - 0.98)	0.81 (0.69 – 0.94)
SLP	Placebo a	4.67 ms (4.21 - 5.36)	4.5 ms (4.2 - 5.4)	4.1 ms (3.7 – 4.4)
	Brazoexperimental	6.90 ms (6.51 - 7.20)	5.7 ms (5.5 - 6.2)	5.7 ms (5.2 – 6.2)
	Δ SLP	2.23 ms	1.2 ms	1.6 ms
	HR	0.758 (0.661 - 0.869)	0.79 (0.70 - 0.90)	0.68 (0.59 – 0.78)
TR	Placebo	11.1% (8.5% - 13.8%)	12.5%	4%
	Brazo experimental	19.8% (16.4% - 23.2%)	13.4%	5%